Controlling alpha in a clinical trial: the case for secondary endpoints

Stat Med. 2000 Mar 30;19(6):763-6. doi: 10.1002/(sici)1097-0258(20000330)19:6<763::aid-sim517>3.0.co;2-8.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Clinical Trials as Topic*
  • Data Interpretation, Statistical*
  • Humans
  • Research Design